ClinicalTrials.gg
CompletedNCT02173457CMASUpdated Oct 25, 2019

Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

A Phase 3 interventional study of Chiglitazar and Sitagliptin in Type 2 Diabetes, sponsored by Chipscreen Biosciences, Ltd.. Completed at 37 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-25.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
740
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
109th of 767
740 · median 199
Started
2014
with 31 others
Phase 3
207 of 909
38 open now
Registered
200th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 109th largest by enrollment of the 767 interventional ones that give a count, is one of 32 that started in 2014, is one of 207 in phase 3, and was the 200th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with Sitagliptin.

Read the detailed description

The efficacy and safety will be compared between Chiglitazar and Sitagliptin after treatment of 24 weeks.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Chiglitazar
  • Sitagliptin
  • diabetes
  • type 2 diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999);
  2. ≥ 7.5% and ≤ 10.0% after control of diet and exercises;
  3. Male and female,age between 18 and 70 years;
  4. between 18.5-35kg/m2;
  5. Willing to be assigned to any treatment arm and sign inform consent.

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes;
  2. Treated by oral or injective antidiabetic drug before screening, including insulin and herb;
  3. Fasting plasma glucose > 13.3 mmol/L (240 mg/dL);
  4. Resistant hypertension [blood pressure above the goal despite adherence to at least 3 optimally dosed antihypertensive medications (including diuretic) of different classes,or blood pressure is controlled to below the goal by at least different classes of drugs];
  5. Plasma triglyceride > 500 mg/dL (5.65 mmol/L);
  6. Is treating by fibrates;
  7. History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy;
  8. Had ,cerebrovascular accident or unstable angina in the past 6 months;
  9. History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery;
  10. Had or is having pancreatic diseases;
  11. Heart failure ( classification Stage III or IV), or left ventricular hypertrophy indicated by ;
  12. Hepatic diseases such as hepatocirrhosis, active hepatitis, or alanine aminotransferase > 2.5 fold of the ;
  13. Kidney diseases or serum creatinine exceed the normal range: male > 133 μmol/L or female >108 μmol/L;
  14. Had in the past 5 years, not including basal cell carcinoma;
  15. Had or is currently receiving treatment that can alter blood glucose metabolism, including but not limited to diuretic,hormone (corticotropin or ),beta blockers;
  16. Have the diseases that can alter blood glucose metabolism, including but not limited to active hepatitis, hyperthyroidism,or adrenal tumors;
  17. Edema with unknown reason;
  18. Alcohol or drug addiction;
  19. Had participated other drugs' clinical trials in the 3 months before screening;
  20. Pregnant or lactic women; or women of childbearing age who are not able to or is not willing to conduct ;
  21. Any condition that make investigator consider the subject is not suitable to participate the trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
740 participants (actual)

Study arms

  • Experimental
    Arm 1

    Patients administrate Chiglitazar 32mg once daily for 24 weeks

    Drug: Chiglitazar

  • Experimental
    Arm 2

    Patients administrate Chiglitazar 48mg once daily for 24 weeks

    Drug: Chiglitazar

  • Active comparator
    Arm 3

    Patients administrate Sitagliptin 100mg once daily for 24 weeks

    Drug: Sitagliptin

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c from baseline after 24 weeks of treatment

    The change of HbA1c at week 24 from baseline

    Time frame: 24 weeks

Secondary outcomes

  1. Change in HbA1c from baseline for patients with a baseline HbA1c >=8.5%

    The change of HbA1c at week 24 from baseline for patients with a HbA1c \>=8.5% at baseline

    Time frame: 24 weeks

  2. Change in HbA1c from baseline for patients with a baseline HbA1c <8.5%

    The change of HbA1c at week 24 from baseline for patients with a HbA1c \< 8.5% at baseline

    Time frame: 24 weeks

  3. Change in HbA1c from baseline

    The change of HbA1c at week 12 from baseline

    Time frame: 12 weeks

  4. Percentage of patients that attained target HbA1c <7.0%

    Percentage of patients whose HbA1c at week 24 are \< 7.0%

    Time frame: 24 weeks

  5. Percentage of patients whose HbA1c lowered by at least 0.5%

    Percentage of patients whose change of HbA1c at week 24d from baseline are \>= 0.5%

    Time frame: 24 weeks

  6. Change in fasting plasma glucose from baseline

    The change of fasting plasma glucose at week 12 and 24 from baseline

    Time frame: 12 and 24 weeks

  7. Change in 2-h postprandial glucose (2hPPG) from baseline

    The change of 2-h postprandial glucose (2hPPG) at week 12 and 24 from baseline

    Time frame: 12 and 24 weeks

  8. Change in total cholesterol (TC) from baseline

    The change of total cholesterol (TC) at week 12 and 24 from baseline

    Time frame: 12 and 24 weeks

  9. Change in triglyceride from baseline

    The change of triglyceride at week 12 and 24 from baseline

    Time frame: 12 and 24 weeks

  10. Change in high density lipoprotein cholesterol (HDL-C) from baseline

    The change of high density lipoprotein cholesterol (HDL-C) at week 12 and 24 from baseline

    Time frame: 12 and 24 weeks

  11. Change in low density proprotein cholesterol (LDL-C) from baseline

    The change of low density lipoprotein cholesterol (LDL-C) at week 12 and 24 from baseline

    Time frame: 12 and 24 weeks

  12. Change in free fatty acid (FFA) from baseline

    The change of free fatty acid (FFA) at week 12 and 24 from baseline

    Time frame: 12 and 24 weeks

  13. Change in fasting plasma insulin from baseline

    The change of fasting plasma insulin at week 12 and 24 from baseline

    Time frame: 12 and 24 weeks

  14. Insulin sensitivity assessed by the homeostatic model assessment (HOMA) at 12 and 24 weeks, compared with that of baseline

    The change of insulin sensitivity at week 12 and 24 from baseline

    Time frame: 12 and 24 weeks

  15. Change in blood pressure from baseline

    The change of blood pressure at week 24 from baseline

    Time frame: 24 weeks

  16. Percentage of patients who discontinue the trial due to hyperglycemia

    The percentage of patients who discontinue the trial due to hyperglycemia during the 24 weeks of treatment

    Time frame: 24 weeks

07

Study locations

37 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
  • The First Hospital Affiliated to Anhui Medical University
    Hefei, Anhui 230022, China
  • Fuwai Hospital
    Beijing, Beijing 100037, China
  • The General Hospital of the Chinese People's Armed Police Forces
    Beijing, Beijing 100039, China
  • Beijing Tiantan Hospital
    Beijing, Beijing 100050, China
  • The Second Artillery General Hospital of Chinese People's Liberation Army
    Beijing, Beijing 100068, China
  • Beijing Tongren Hospital Affiliated to Capital Medical Universtiy
    Beijing, Beijing 100730, China
  • The Third Hospital Affiliated to Guangzhou Medical College
    Guangzhou, Guangdong 510360, China
  • The Second Affiliated Hospital of Shantou University Medical College
    Shantou, Guangdong 512021, China
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518000, China
  • Beijing University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • Zhongshan People's Hospital
    Zhongshan, Guangdong 528403, China
  • The First Affiliated Hospital of Guangxi Medical University (The Eastern Hospital)
    Nanning, Guangxi 530021, China
  • The First Affiliated Hospital of Guangxi Medical University (The Western Hospital)
    Nanning, Guangxi 530021, China
  • The Second Hospital of Heibei Medical University
    Shijiazhuang, Hebei 050000, China
  • Tongji Hospital Affiliated to Tongji Medical College of HUST
    Wuhan, Hubei 430030, China
  • The First Hospital Affiliated to Nanhua University
    Hengyang, Hunan 421001, China
  • The First People's Hospital of Yueyang
    Yueyang, Hunan 414000, China
  • The Affiliated Hospital of Inner Mongolia
    Hohhot, Inner Mongolia 010050, China
  • Huai'an First People's Hospital
    Huai'an, Jiangsu 223300, China
  • Gulou Hospital Affiliated to Nanjing Medical University
    Nanjing, Jiangsu 210008, China
  • The Second Hospital Affiliated to Nanjing Medical University
    Nanjing, Jiangsu 210009, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210029, China
  • The Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212013, China
  • The First Hospital of Jilin University
    Changchun, Jilin 100031, China
  • Siping Central People's Hospital
    Siping, Jilin 136000, China
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116044, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Shanghai Changzheng Hospital
    Shanghai, Shanghai 200003, China
  • The Qingpu Branch of Zhongshan Hospital Affiliate to Fudan University
    Shanghai, Shanghai 200043, China
  • Tongji Hospital Affiliated to Tongji University
    Shanghai, Shanghai 200065, China
  • Shanghai First People's Hospital
    Shanghai, Shanghai 200080, China
  • Shanghai 6th People's Hospital
    Shanghai, Shanghai 200235, China
  • Shanghai 5th People's Hospital
    Shanghai, Shanghai 200240, China
  • The Central Hospital of Minhang District of Shanghai
    Shanghai, Shanghai 201199, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710061, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
08

References and documents

Publications

  • Zhou Y, Wang H, Wang Y, Xu X, Li F, Zhou J, Shan T, Huang R, Cai T, Liu X, Su X, Li H, Ma J. Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes. Front Endocrinol (Lausanne). 2022 Apr 25;13:801271. doi: 10.3389/fendo.2022.801271. eCollection 2022. PubMed 35547000 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Jan 2017, 28 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 28 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 25, 2014
StartActual
Sep 2014
Primary completionActual
Jan 2017
CompletionActual
Jan 2017
Last update
Oct 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02173457
Responsible party
Sponsor
First posted
Jun 25, 2014
Start date
Sep 2014
Primary completion
Jan 2017
Completion
Jan 2017
Last update
Oct 25, 2019

Study contacts

Weiping Jia, Dr.
principal investigator · Shanghai 6th People's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiglitazar

Start the discussion